Eliem Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-35.12	-45.24	-52.03	-22.95	-7.39
Depreciation & Amortization	0.41	0.44	0	0	0
Share-Based Compensation	12.81	6.99	3.74	0.71	0
Other Operating Activities	1.31	0.44	7.67	5.86	1.54
Operating Cash Flow	-20.6	-37.37	-36.07	-14.1	-5.01
Acquisitions	0	0	0	8.08	0
Change in Investments	68.98	34.44	-114.97	0	0
Investing Cash Flow	68.98	34.44	-114.97	8.08	0
Share Issuance / Repurchase	0.84	0	83.29	0	0
Other Financing Activities	-	-	93.94	4.93	26.24
Financing Cash Flow	0.84	0	177.23	4.93	26.24
Exchange Rate Effect	0.3	-0.41	0.25	0.36	-0.01
Net Cash Flow	49.53	-3.34	26.44	-0.74	21.22
Free Cash Flow	-20.6	-37.37	-36.07	-14.1	-5.01
Free Cash Flow Per Share	-0.76	-1.42	-2.94	-6.44	-3.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).